Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
NCT06039891
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
55
Enrollment
OTHER
Sponsor class
Conditions
Cervical Cancer
Interventions
DRUG:
Nimotuzumab、Tislelizumab
Sponsor
Peking Union Medical College Hospital